Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$61.98
neg -0.44
-0.70%
Today's Range: 61.80 - 62.76 | TEVA Avg Daily Volume: 4,467,900
Last Update: 03/27/15 - 4:02 PM EDT
Volume: 4,456,792
YTD Performance: 8.54%
Open: $62.14
Previous Close: $62.42
52 Week Range: $47.36 - $63.07
Oustanding Shares: 851,871,888
Market Cap: 52,194,190,578
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 11 11
Moderate Buy 1 1 1 1
Hold 9 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.86 1.95 1.95 1.95
Latest Dividend: 0.29
Latest Dividend Yield: 1.88%
Dividend Ex-Date: 02/17/15
Price Earnings Ratio: 41.12
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
41.12 17.20 27.33
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.16% 27.70% 42.19%
GROWTH 12 Mo 3 Yr CAGR
Revenue -0.20 0.11 0.03
Net Income 142.80 0.10 0.03
EPS 138.50 0.15 0.05
Earnings for TEVA:
EBITDA 6.00B
Revenue 20.27B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.26 $1.28 $5.16 $5.18
Number of Analysts 12 11 17 14
High Estimate $1.38 $1.32 $5.30 $5.55
Low Estimate $1.17 $1.23 $5.04 $4.46
Prior Year $1.22 $1.23 $5.07 $5.16
Growth Rate (Year over Year) 3.14% 4.29% 1.87% 0.35%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Here are healthcare stocks of all shares and sizes with strong charts.
This vaccine maker is now closer to several important milestones.
A transformational deal with Teva makes it an even better play.
A transformational deal with Teva makes it an even better play.

Small-Cap Friday's Little Gem Real Money Pro($)

One small pharmaceutical company has big potential.

Take a Look at Teva Real Money Pro($)

We like new initiatives and see solid upside potential.
Bullish
Dec 12, 2014 | 8:15 AM EST
TEVA was upgraded from Neutral to Buy, Sterne Agee said. $65 price target. Estimates also upped, given the company's new guidance. ...

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Investing during a mid-term election can offer large returns.
Bullish
Aug 04, 2014 | 7:56 AM EDT
TEVA price target raised from $50 to $54, UBS said. Neutral rating. Estimate also raised due to higher base sales.

Columnist Conversations

Darden Restaurant's (DRI) CFO sold 66,863 shares on March 24, 2015 for an average price of $69.68. Proceeds to...
We did not end up holding the pullback to the last time/price low in NFLX. I have run some new price relation...
The Biotech iShares (IBB) fund closed up nearly 2% on the day, but was down over 5% on the week. Today's volu...
Full on breakout for shares of CAG today. The earnings inspired ramp(+5.5%)has it in the number 3 spot o...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.